AstraZeneca signs deal to sell commercial rights for Seloken in Europe

AstraZeneca has entered an agreement to provide the commercial rights for Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments i …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news